Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    COVIDcast - Tocilizumab [RECOVERY trial]

    COVIDcast - Tocilizumab [RECOVERY trial]

    FromFOAMcast - An Emergency Medicine Podcast

    Start listeningView podcast show

    COVIDcast - Tocilizumab [RECOVERY trial]

    FromFOAMcast - An Emergency Medicine Podcast

    ratings:
    Length:
    13 minutes
    Released:
    Feb 13, 2021
    Format:
    Podcast episode

    Description

    Early studies of tocilizumab, a monoclonal antibody that binds interleukin-6 , were disappointing. However, the REMAP-CAP trial recently reported a benefit to tocilizumab in non-critically ill hospitalized patients with COVID-19. Now, from the RECOVERY trial (the trial that brought us dexamethasone), we have more good news for tocilizumab - which we cover in this podcast Show notes: FOAMcast.org Thanks for listening! Lauren Westafer and Jeremy Faust
    Released:
    Feb 13, 2021
    Format:
    Podcast episode

    Titles in the series (100)

    We review a cutting edge a Free Open Access Medical Education (FOAM) blog or podcast and then delve into the Emergency Medicine Core Content texts on relevant issues and end with free board review questions. We believe in the educational merits of Free Open Access Medical education (FOAM), which includes podcasts, blogs, articles on PubMed Central, conferences streamed for free and more. As a result, we would like to encourage others to move beyond quoting podcasts and into the realm of tying “cutting edge” FOAM to the core content. Why, indeed, should we FOAM it alone when FOAM can inspire us to go, read, think, and be excellent? Thanks for listening, Jeremy Faust and Lauren Westafer